Nasdaq cprx.
If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...
Earnings vs Savings Rate: CPRX's forecast earnings growth (25.8% per year) is above the savings rate (2.2%). Earnings vs Market: CPRX's earnings (25.8% per year) are forecast to grow faster than the US market (14.7% per year). High Growth Earnings: CPRX's earnings are expected to grow significantly over the next 3 years.Past criteria checks 1/6. Catalyst Pharmaceuticals has been growing earnings at an average annual rate of 41.7%, while the Biotechs industry saw earnings …For the last reported quarter, Catalyst came out with earnings of $0.20 per share versus the Zacks Consensus Estimate of $0.19 per share, representing a surprise of 5.26%. For the previous quarter ...(Nasdaq: CPRX) announced today that it has entered into definitive agreements to sell (i) 4.0 million shares of the Company's common stock, and (ii) common ...CPRX Stock 12 Months Forecast. $23.30. (81.32% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Catalyst Pharma in the last 3 months. The average price target is $23.30 with a high forecast of $27.00 and a low forecast of $15.50. The average price target represents a 81.32% change from the last price of $12.85.
CPRX technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Catalyst Pharmaceuticals, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and …Find the latest news headlines from Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.
The latest price target for Catalyst Pharmaceuticals (NASDAQ: CPRX) was reported by Cantor Fitzgerald on Tuesday, August 22, 2023. The analyst firm set a price ...
Oct 28, 2021 · Most readers would already be aware that Catalyst Pharmaceuticals' (NASDAQ:CPRX) stock increased significantly by 9.4% over the past month. Since the market usually pay for a company’s long-term ... CPRX U.S.: Nasdaq Catalyst Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023 7:46 p.m. EST Delayed quote $ 13.68 -0.13 -0.94% After Hours... (NASDAQ: CPRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.13%. What is CPRX's Price Target? According to 3 Wall Street analyst s that have issued a 1 year CPRX price target, the average CPRX price target is $25.00 , with the highest CPRX stock price forecast at $27.00 and the lowest CPRX …Feb 28, 2023 · Catalyst Pharmaceuticals (NASDAQ:CPRX) is another biotech that has performed strongly over the past twelve months. During this timeframe, shares have nearly doubled in price. During this timeframe ...
Will Weakness in Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Prove Temporary Given Strong Fundamentals? (Simply Wall St.) Jul-19- ...
Dec 12, 2022 · Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company that focuses on therapies for rare debilitating, chronic neuromuscular, and neurological ...
Find the latest Insider Activity data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com. Read more to see why CPRX stock is a Strong Buy. Catalyst Pharmaceuticals expects its 2Q, 3Q, and 4Q 2023 revenues to be higher than in 1Q. ... (NASDAQ:CPRX) stock price is down 25%, despite the ...Fintel reports that on August 11, 2023, Cantor Fitzgerald maintained coverage of Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight recommendation. Analyst Price Forecast Suggests 52.12% UpsideAccording to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...CPRX earnings call for the period ending September 30, 2021. Image source: The Motley Fool. Catalyst Pharmaceuticals, inc ( CPRX -1.16% ) Q3 2021 Earnings Call Nov 10, 2021 , 8:30 a.m. ETCPRX CPRX AFTER HOURS QUOTE CPRX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ... CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...
Cetera Investment Advisers grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 7.8% during the second …Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) stock closed at 14.05 per share at the end of the most recent trading day (a -1.13 % change compared to the prior day closing price) with a volume of 1.06M shares and market capitalization of 1.54B.Is a component of indices and it is traded on NASDAQ exchange. The company belongs in …The average twelve-month price prediction for Catalyst Pharmaceuticals is $24.75 with a high price target of $27.00 and a low price target of $24.00. Learn more on CPRX's analyst rating history. Do Wall Street analysts like Catalyst Pharmaceuticals more than its competitors? Analysts like Catalyst Pharmaceuticals more than other Medical companies. Jul 30, 2021 · You can take a look at the company's revenue and earnings growth trend, in the chart below. To see the actual numbers, click on the chart. NasdaqCM:CPRX Earnings and Revenue History July 30th 2021 Past criteria checks 1/6. Catalyst Pharmaceuticals has been growing earnings at an average annual rate of 41.7%, while the Biotechs industry saw earnings …Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, focused on developing and commercializing therapies for patients with rare debilitating ...
Stock analysis for Catalyst Pharmaceuticals Inc (CPRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Shareholders in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts greatly ...CPRX CPRX AFTER HOURS QUOTE CPRX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ...Jul 30, 2021 · You can take a look at the company's revenue and earnings growth trend, in the chart below. To see the actual numbers, click on the chart. NasdaqCM:CPRX Earnings and Revenue History July 30th 2021 CPRX CPRX AFTER HOURS QUOTE CPRX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ...CPRX U.S.: Nasdaq Catalyst Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023 7:46 p.m. EST Delayed quote $ 13.68 -0.13 -0.94% After Hours...CPRX technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Catalyst Pharmaceuticals, Inc. is based on the …CPRX U.S.: Nasdaq Catalyst Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023 7:46 p.m. EST Delayed quote $ 13.68 -0.13 -0.94% After Hours...
(NASDAQ:CPRX), announced on June 20, 2023 [1]. The proceeds from the agreement extend Santhera's cash reach into 2025. Together with the expected income ...
Apr 13, 2021 · A look at the shareholders of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership.
(CPRX). NASDAQ: CPRX · IEX Real-Time Price · USD. Add to Watchlist. 14.06. +0.20 (1.44%). At close: Nov 24, 2023, 1:00 PM. 13.82. -0.24 (-1.71%). After-hours: ...CORAL GABLES, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has successfully completed …The price-to-earnings ratio for Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) is above average at 12.30x, while the 36-month beta value is 1.08.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”Then look at the Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) share price. It's 715% higher th Shareholders Are Raving About How The Catalyst Pharmaceuticals (NASDAQ:CPRX) Share Price Increased ...Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, engaged in the development and commercialization of therapies for rare debilitating ...Right now, Catalyst has an S/TA ratio of 0.71, which means that the company gets $0.71 in sales for each dollar in assets. Comparing this to the industry average of 0.27, it can be said that the ...Jan 31, 2023 · Catalyst Pharma (NASDAQ:CPRX) is a $1.6bn market cap (at the time of writing) Florida based commercial stage biotech that markets and sells a single product - the neuronal potassium channel ... Dec 1, 2023 · A high-level overview of Catalyst Pharmaceuticals, Inc. (CPRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Nov 30, 2023 · The stock price of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has plunged by -1.13 when compared to previous closing price of 14.21, but the company has seen a 2.26% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-11-09 that Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales […] Catalyst Pharmaceutical (CPRX) closed at $16.60 in the latest trading session, marking a -0.12% move from the prior day. This move was narrower than the S&P 500's daily loss of 0.7%.Aug 9, 2022 · Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.16 per share a year ago. Catalyst Pharmaceuticals, Inc. (CPRX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Catalyst Pharmaceuticals, ...
That number of contracts represents approximately 900,900 underlying shares, working out to a sizeable 56.5% of CPRX's average daily trading volume over the past month, of 1.6 million shares.Catalyst also expects a cash balance of $191 million as of 2021-end, without any funded debt. For 2022, the company expects total revenues for 2022 in the range of $195-$205 million, suggesting a ...A high-level overview of Catalyst Pharmaceuticals, Inc. (CPRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Instagram:https://instagram. best dental insurance mainepercent.com reviewpro firmex dividend record date For the last reported quarter, Catalyst came out with earnings of $0.20 per share versus the Zacks Consensus Estimate of $0.19 per share, representing a surprise of 5.26%. For the previous quarter ... best hedge fund managersnintedo stock Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, focused on developing and commercializing therapies for patients with rare debilitating ...LPL Financial LLC trimmed its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 49.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC).The institutional investor owned 33,878 shares of the … interior sewer line insurance Catalyst Pharmaceuticals had non-GAAP profits of 41 cents, a full dime a share over the consensus. On a GAAP basis, earnings were 26 cents a share for the quarter, an improvement of 117% from ...Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.16 per share a year ago.